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Abstract
Low-intensity electrical current (or mild electrical stimulation; MES) influences signal transduction and activates
phosphatidylinositol-3 kinase (PI3K)/Akt pathway. Because insulin resistance is characterized by a marked reduction in
insulin-stimulated PI3K-mediated activation of Akt, we asked whether MES could increase Akt phosphorylation and
ameliorate insulin resistance. In addition, it was also previously reported that heat shock protein 72 (Hsp72) alleviates
hyperglycemia. Thus, we applied MES in combination with heat shock (HS) to in vitro and in vivo models of insulin
resistance. Here we show that 10-min treatment with MES at 5 V (0.1 ms pulse duration) together with HS at 42uC increased
the phosphorylation of insulin signaling molecules such as insulin receptor substrate (IRS) and Akt in HepG2 cells
maintained in high-glucose medium. MES (12 V)+mild HS treatment of high fat-fed mice also increased the phosphorylation
of insulin receptor b subunit (IRb) and Akt in mice liver. In high fat-fed mice and db/db mice, MES+HS treatment for 10 min
applied twice a week for 12–15 weeks significantly decreased fasting blood glucose and insulin levels and improved insulin
sensitivity. The treated mice showed significantly lower weight of visceral and subcutaneous fat, a markedly improved fatty
liver and decreased size of adipocytes. Our findings indicated that the combination of MES and HS alleviated insulin
resistance and improved fat metabolism in diabetes mouse models, in part, by enhancing the insulin signaling pathway.
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Introduction
It has been established that direct-current electrical fields impact
on cellular functions [1]. Positive medical effects of applied low
electric current, such as decreased inflammation, bone-fracture
healing and alleviation of pain have been reported [2,3,4]. Low-
intensity electric fields have also been shown to inhibit tumor
growth in vitro [5] and in vivo with no serious side effects [6]. It is
hypothesized that the therapeutic effects of applied low electrical
field strength are due to enhanced signal transduction [7], a
hypothesis that was partly validated by a study demonstrating that
electrical signals promote wound healing through the activation of
phosphatidylinositol-3-OH kinase (PI3 kinase) and Akt [8].
Insulin resistance, which characterizes type 2 diabetes, is
manifested by decreased insulin-stimulated glucose transport and
metabolism [9,10]. This functional defect is partly due to a
decrease in insulin-stimulated Akt activation and failure in the
translocation of glucose transporter GLUT4 to the cell surface
[11,12,13]. There is consensus that a marked reduction in insulin-
stimulated PI3K-mediated activation of Akt results in decreased
insulin sensitivity in vivo [14,15,16,17]. Thus, enhancing Akt
phosphorylation could alleviate insulin resistance.
Further studies have elucidated that insulin resistance could also
be attributed to the serine phosphorylation of IRS-1, which is
mediated by the activity of c-Jun N-terminal kinase (JNK) [18,19].
It is now known that the activation of JNK is prevented by cellular
protective actions of Hsp72 [20,21,22] and this implies a possible
role of Hsp72 in ameliorating insulin resistance (reviewed in [23]).
A recent report suggests that Hsp72 overexpression improved
insulin resistance in high fat-fed mice [24]. Therefore Hsp72,
which can be up-regulated by HS, may have an essential role in
preventing insulin resistance.
In this study, we assessed the effects of heat shock (HS) together
with mild electrical stimulation (MES) on insulin resistance in
cellular and animal models. HS was produced by infrared rays, and
low-intensity direct electrical current was delivered through
insulated electrodes. Our results showed that HS+MES increased
the insulin-stimulated phosphorylation of Akt in HepG2 cells
maintained in high-glucose medium, which we used here as an in
vitro model of insulin resistance. Moreover, HS+MES improved the
hyperglycemic phenotype and fat metabolism in high fat-fed mice.
Materials and Methods
Antibodies
The antibodies used in this study were: mouse anti-Hsp72 (SPA-
810), rabbit anti-Hsp72 (SPA-812) and rabbit anti-calnexin (C-
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(Victoria, BC, Canada); mouse anti-c-Myc (9E10; sc-40), rabbit
anti-IRS-1 (sc-559), and rabbit anti-phospho insulin receptor b-
subunit (Tyr 1162/1163; sc-25103), from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA); rabbit antibodies from Cell Signaling
Technology (Danvers, MA): anti-phospho-Akt (Ser 473), anti-Akt,
anti-phospho-JNK (Thr183/Tyr185), anti-JNK and anti-phospho-
(Tyr) p85PI3K binding motif.
Cell culture and in vitro HS+MES treatment
Human hepatocyte cell line, HepG2 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum and antibiotics. Cells were plated on 60-mm
culture dishes, and at 80% confluency were treated with HS and/
or MES. For MES, the culture plate cover was exchanged with a
plate cover slit at the sides designed to accommodate insulated
wires bearing a pair of flat rubber electrodes, which were fitted at
the walls of the culture plate and in contact with the culture media
(Fig. 1A). The electrodes were connected to a Biometronome
TM
(Tsuchiya Gum Co., Ltd., Kumamoto, Japan). Electrical stimu-
lation for cells was delivered using 5 V (55 pulses per second (pps))
of direct current with individual pulse duration of 0.1 ms [25].
The culture plate with the electrodes was carefully sealed and
immersed in water bath at a temperature of 42uC. Simultaneous
treatment with HS and MES was carried out for 10 min. After
treatment, the medium was changed and cells were re-incubated
at 37uC until assay. For control, cells were sham treated by setting
up the electrodes in a similar manner as described above but
without HS+MES.
Animals and in vivo HS+MES treatment
Five-week-old male C57BL/6J mice and db/db mice (BKS.Cg-
m+/+Leprdb/J: Leprdb/Leprdb mice; Charles River Laboratories,
Inc., Kanagawa, Japan), were housed in a vivarium in accordance
with the guidelines of the animal facility center of Kumamoto
University. The mice were maintained on food (standard or high-fat
diet) and water ad libitum. High-fat diet was composed of 14% lard,
14% beef tallow, 25% casein, 20% sucrose, 15% cornstarch, 5%
cellulose. Six-week-old or 25-week-old mice were treated with HS
and/or MES. A well-ventilated 12 cm610 cm (width6height)
chamber was designed for the animal treatment. Electrical
stimulation was delivered to un-anesthetized test animal through a
pair of 10-cm diameter electro-conductive and thermo-generative
rubber electrodes, which were padded with moist soft cotton cloth.
The electrodes can be adjusted to allow contact with the animal
(Fig. 1B). The electrodes are connected to a Biometronome
TM
(Tsuchiya Gum Co., Ltd.) that delivered 12 V (55 pps) of direct
current with individual pulse duration of 0.1 ms. The temperature
at the surfaceof the electrodes was adjusted to 42uC. For the control
group,micewere shamtreated byputtingthem inthechamber with
similar set-up as above for 10 min per session but without
conducting HS+MES. All procedures involving these animals were
approved by the Animal Care and Use Committee of Kumamoto
University (#A19-115).
Induction of insulin resistance in HepG2 cells
HepG2 cells were incubated in serum-free DMEM containing
normal concentrations of glucose (5.5 mM D-glucose) for 16 h and
were additionally incubated in serum-free DMEM containing
either normal or high concentrations of glucose (25 mM D-
glucose) for 24 h. During HS and/or MES treatment, cells were
kept under normal or high glucose concentration. Cells were
incubated with 100 nM insulin for 10 min prior to protein
isolation.
Immunoblotting
Protein lysates from HepG2 cells were isolated with radioimmu-
noprecipitation assay (RIPA) buffer [26] or lysis buffer (25 mM
HEPES, 10 mM Na4P2O7?10H2O, 100 mM NaF, 5 mM EDTA,
2m MN a 3VO4, 1% Triton X-100). Mice tissues were lysed and
sonicated in glycerol buffer [27]. Protein lysates were subjected to
SDS-PAGE and Western blotting in the same manner as described
previously [27]. The blots were probed with the indicated antibodies
and their respective HRP-conjugated secondary antibodies obtained
from Jackson ImmunoResearch Laboratories (West Grove, PA). The
proteins were reacted with chemiluminescence reagent ECL
(Amersham Pharmacia Biotech, UK) for visualizing the blots.
Immunofluorescent staining
HepG2 cells on cover glasses were incubated and then fixed with
10% formalin. PIP3 and GLUT4 expressions were analyzed by
immunohistochemistry in the same manner as described previously
[28]. After PBS equilibration, slides or liver tissue sections were
incubated with 3% normal goat serum in 2.5% Triton X-100/PBS
for 1 or 2 h at room temperature for blocking. Incubation with a
primary antibody to PIP3 (Echelon Biosciences Inc., Salt Lake City,
UT, USA; 1/100 dilution) was performed overnight in blocking
solution at 4uC. After washes with PBS, slides or sections were
incubated with Alexa Fluor 546 or Alexa Fluor 488 (Molecular
Probes, OR, USA), and DAPI (Dojindo, Kumamoto, Japan)
Figure 1. Diagram of apparatus for HS+MES treatment. (A)
HS+MES treatment set-up for HepG2 cells. (B) HS+MES treatment set-up
for mice.
doi:10.1371/journal.pone.0004068.g001
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three washes with PBS, slides or sections were mounted with
ProLong Antifade kit (Molecular Probes) and examined with
fluorescent microscope, BZ-8000 (KEYENCE, Osaka, Japan).
Hsp72 plasmid, siRNA and transfection
A full-length cDNA for human Hsp72 (Hsp70A1A) was obtained
using primers: 59-primer, CTAGGATCCGTGTTCCGTTTC-
CAG; and 39-primer, GACGAATTCCTCAATGGTGGGGCCT.
The PCR product was cloned into pCR2.1 vector using a TA cloning
kit (Invitrogen, Carlsbard, CA, USA). Hsp72 tagged with c-Myc in
the C-terminus was constructed by subcloning Hsp72 into the
BamHI-EcoRI sites of pCMV-Tag5 vector (Stratagene, La Jolla, CA,
USA). Transient transfection of plasmid DNA was performed for
48 h using HilyMax (Dojindo, Kumamoto, Japan) according to the
manufacturer’s recommendations. Hsp72 siRNA was designed;
sense, 59-GGAGCUGGAGCAGGUGUGUTT-39 and anti-sense,
59-ACACACCUGCUCCAGCUCCTT-39.G L 2( L u c i f e r a s e )
siRNA duplex was used as control for siRNA transfection; sense,
59-CGUACGCGGAAUACUUCGATT-39 and anti-sense, 59-UC-
GAAGUAUUCCGCGUACGTT-39. Transient transfection of
siRNA duplex was performed for 24 h using TransIT-TKO (Mirus,
Madison, WI, USA) following the manufacturer’s protocol.
Blood analysis and HOMA-IR index
Blood glucose was assayed with ACCU-CHEK Compact (Roche
Diagnostics,Mannheim,Germany).Seruminsulin,adiponectinand
TNF-a weredetermined withLipoSEARCH (Skylight BiotechInc.,
Akita, Japan). HOMA-IR was calculated using the following
formula: fasting blood glucose6fasting insulin/22.5 [29].
Glucose and insulin tolerance tests
Glucose tolerance test was performed on fasted (15 hr) mice.
Mice received an injection of glucose (2 g/kg body wt), and blood
glucose was assayed immediately before and at the indicated time
after glucose administration. Insulin tolerance test was performed
on fasted (6 h) mice. Mice received an injection of human regular
insulin (2 units/kg body wt; Novo Nordisk, Copenhagen, Denmark)
into the intraperitoneal space, and blood glucose was assayed
immediately before and at the indicated time after injection.
RT-PCR
Total RNA was collected from mice brown adipose tissue using
Isogen (Nippongene, Tokyo, Japan). RT-PCR experiments were
performed with an RT-PCR kit (Takara, Ohtsu, Japan) according
to the manufacturer’s instructions. The following primers were
used for UCP1: up, 59-TTTGGAAAGGGACGACCCCTAATC-
39, and down, 59-ACCCGAGTCGCAGAAAAGAAGC-39; for
HPRT: up, 59-GTTGGATACAGGCCAGACTTTGTTG-39,
and down, 59-GATTCAACTTGCGCTCATCTTAGGC-39.
Statistical analysis
Data are presented as mean6S.E. Significance of the difference
between groups were assessed with Student’s unpaired two-tailed t
test (when 2 groups were analyzed) or one-way ANOVA (for $3
groups). A P value of ,0.05 was considered statistically significant.
Results
Treatment with HS+MES ameliorated hyperglycemia in
high fat-fed mice
We assessed the effect of HS+MES treatment on hyperglycemia
in vivo using high fat-fed mice. Five-week old male C57BL/6J mice
were fed with a high-fat diet. One week after starting the high-fat
diet, mice were sham-treated or treated with HS+MES for 10 min
twice a week for 12–15 weeks. A low current (12 V; 0.1 ms) was
well tolerated and did not cause pain or annoyance behavior in
mice as observed by their tendency to stay still and occasionally
doze off during treatment. After 12 weeks of treatment, we
measured various blood parameters. The fasted blood glucose
level was significantly lower in high fat-fed mice treated with
HS+MES (Fig. 2A). Although the fasted blood glucose was also
decreased in HS-treated group (Fig. 2A), the fasted insulin level in
this group was not significantly lower compared with sham-treated
group (Fig. 2B). On the other hand, the fasted insulin level was
reduced significantly in HS+MES-treated mice after 9 to 12 weeks
of treatment compared with control mice (Fig. 2B). At a similar
time point, the HS+MES-treated mice had significant increase of
adiponectin (Fig. 2C). HS+MES markedly improved glucose
tolerance in high fat-fed mice as indicated by intraperitoneal
glucose tolerance test (Fig. 2D). Homeostasis model assessment of
insulin resistance, HOMA-IR index was also significantly
improved in HS+MES-treated mice (Fig. 2E). Body weight and
food intake did not differ between the control and treated groups
(Fig. 2F,G).
Treatment with HS+MES ameliorated hyperglycemia in
mice chronically fed with high-fat diet
We next examined the effect of HS+MES on mice fed with high-
fat diet for 5 months. Body weight of high fat-fed mice was
remarkably higher than those fed a standard diet (Fig. 3A).
Moreover, the fasting blood glucose level of these high fat-fed mice
significantly increased after 3–5 months of feeding on high-fat diet
(18–25 weeks old vs 7 weeks old; Fig. 3B), indicating an onset of
obesity and hyperglycemia. To determine whether HS+MES
ameliorates hyperglycemia in these high fat-fed mice, we sham
treated or treated this group of mice with HS+MES for 10 min
twice a week for 10 weeks. HS+MES significantly decreased fasting
blood glucose and insulin levels, and increased serum adiponectin
(Fig. 3C–3E). Interestingly, HS+MES also markedly reduced the
level of tumor necrosis factor-a (TNF-a), which is known to
attenuate insulin signaling [30], in high fat-fed mice (Fig. 3F). These
data collectively suggest that HS+MES treatment ameliorated
hyperglycemic phenotype in mice chronically fed with high-fat diet.
Treatment with HS+MES increased the insulin-stimulated
phosphorylation of IRb and Akt in the liver of high fat-fed
mice
The results above suggest that HS+MES might have improved the
insulin signaling in high fat-fed mice. To confirm whether HS+MES
promotes insulin receptor phosphorylation, which initiates insulin
action by phosphorylating multiple intracellular substrates, we
determined the phosphorylation status of IRb in mice liver. Lysates
were extracted from the liver of sham-treated or HS+MES-treated
high fat-fed mice 15 weeks after the start of treatment. Insulin
administration, as expected, increased the IRb phosphorylation
(Fig. 4A, lane 2). Interestingly, HS+MES treatment enhanced the
insulin-stimulated IRb phosphorylation (Fig. 4A, pIRb, lane 4), and
activated IRb downstream molecule, Akt (Fig. 4A, pAkt, lane 4).
Consistent with these results, HS+MES enhanced the immunoreac-
tivity of phosphatidylinositol-3,4,5-triphosphate (PIP3), a second
messenger molecule produced by PI3K activation in mice liver
(Fig. 4B). Moreover, JNK phosphorylation was substantially down-
regulated in liver lysates of HS+MES-treated mice (Fig. 4C; pJNK).
In addition, we observed that HS+MES treatment up-regulated the
level of Hsp72 in the liver of high fat-fed mice (Fig. 4C).
Enhancing Insulin Signaling
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adipose tissues and liver of high fat-fed mice
Since treatment with HS+MES, compared with sham-treated
control, increased the serum adiponectin level (Fig. 2C, 3E), which
is known to be inversely related to the degree of adiposity [16,31],
we investigated whether this treatment decreases adipose tissue in
high fat-fed mice. We found a substantial decrease of white adipose
tissue mass in HS+MES-treated mice compared with control mice
(Fig. 5A). H&E staining showed reduced size of adipocytes in white
adipose tissues of the treated mice (Fig. 5B). Visceral fat and
subcutaneousfatweights and liver weightwerealsoreduced inthese
mice (Fig. 5C–5E). Staining with Oil Red O revealed that the lipid
dropletswereremarkablydecreasedintheliverofHS+MES-treated
mice (Fig. 5F). Moreover, HS+MES significantly increased, in
brownadiposetissue,the mRNAexpressionofuncouplingprotein1
(UCP1; Fig. 5G), which is known to regulate tissue diet-induced
thermogenesis [32]. These results signify that HS+MES treatment
improved the fat metabolism in high fat-fed mice.
Treatment with HS+MES ameliorated hyperglycemia in
db/db mice
To further examine the effect of HS+MES on another mouse
model of type 2 diabetes, we used 6-week-old male db/db mice,
which exhibit defects in leptin receptor and develop obesity
because of hyperphagia and decreased energy expenditure [33].
We used the same condition of treatment as those for the high fat-
fed mice. There were no observable differences in body weight and
food intake between the HS+MES-treated and sham-treated db/
db mice (data not shown). After 12 weeks of HS+MES treatment,
fasted blood glucose and serum insulin levels were significantly
decreased in treated db/db mice (Fig. 6A,B). Insulin tolerance test
suggests that this treatment improved insulin sensitivity in treated
db/db mice (Fig. 6C). Moreover, visceral fat and subcutaneous fat
weights were significantly decreased in HS+MES-treated mice
(Fig. 6D,E). Thus, HS+MES also attenuated insulin resistance
associated with obesity and improved fat metabolism in db/db
mice.
HS+MES showed no adverse effects in standard diet-fed
mice
To determine possible adverse effects of HS+MES treatment in
normal mice, we confirmed various parameters on standard diet-
fed, lean mice. Within 16 weeks of treatment, body weight and
food intake did not differ between HS+MES-treated group and
control group (Fig. 7A,B). HS+MES for 16 weeks did not induce a
difference in the blood glucose levels in standard diet-fed mice
Figure 2. HS+MES ameliorated hyperglycemia in high fat-fed mice. (A) Blood glucose levels of high fat-fed sham-treated, HS and/or MES-
treated mice were measured at the 12
th week of treatment in the 15-h fasted state. (B and C) Serum insulin (B) and adiponectin (C) of high fat-fed
control, HS and/or MES-treated mice were measured every 3 weeks in the 15-h fasted state. (D) Intraperitoneal glucose tolerance test was performed
on mice at the 12
th week of treatment in the 15-h fasted state. Glucose levels were measured at the time points indicated after glucose
administration. Symbols: black diamonds=control; squares=MES; triangles=HS; white diamonds=HS+MES. (E) HOMA-IR was calculated as follows:
fasting glucose6fasting insulin/22.5. Comparison was performed at 12
th week of treatment. (F and G) Body weight (F) and food intake (G) of high fat-
fed control, HS and/or MES-treated mice were measured at the 12
th week of treatment. All data are presented as mean6S.E. (n=6 per group)
*P,0.05, **P,0.01, ***P,0.001 vs. control group, assessed by one-way ANOVA.
doi:10.1371/journal.pone.0004068.g002
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PLoS ONE | www.plosone.org 4 December 2008 | Volume 3 | Issue 12 | e4068Figure 3. HS+MES ameliorated the diabetic phenotype in mice chronically fed with high-fat diet. (A) Six-week old C57BL/6J mice were
fed with standard or high-fat diet for 5 months, and body weight was measured at the indicated time points. Symbols: black circles=standard diet;
white circles=high-fat diet. Data are presented as mean6S.E. (n=10 per group) ***P,0.001 assessed by unpaired t test. (B) Fasting blood glucose
levels of mice fed with high fat-diet were measured at the indicated time points. Data are presented as mean6S.E. *P,0.05, ***P,0.001 vs. 7-week
old mice, assessed by one-way ANOVA. (C–F) Five months after the start of high-fat feeding, mice were sham-treated (control) or treated with
HS+MES for 10 min twice a week for 10 weeks. Blood glucose (C), serum insulin (D), adiponectin (E) and TNF-a (F) of control or HS+MES-treated high
fat-fed mice (n=5 per group) were measured at the 10
th week of treatment in the 15-h fasted state. Data are presented as mean6S.E. *P,0.05
assessed by unpaired t test.
doi:10.1371/journal.pone.0004068.g003
Figure 4. HS+MES improved insulin signaling in the liver of high fat-fed mice. (A) Liver lysates were extracted 15 weeks after initiation of
HS+MES treatment from high fat-fed control and HS+MES-treated mice with or without 5 units of insulin stimulation through inferior vena cava, and
were analyzed by Western blotting. (B) Liver tissues were isolated at the 15
th week after initiation of treatment from high fat-fed control or HS+MES-
treated mice with or without 5 units of insulin stimulation through inferior vena cava. Tissues were dissected in frozen sections, stained with PIP3 and
DAPI, and visualized by fluorescent microscope. Scale bars, 100 mm. (C) Liver lysates extracted from control and HS+MES-treated mice were subjected
to Western blotting analysis using the indicated antibodies.
doi:10.1371/journal.pone.0004068.g004
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examined under fasted and fed conditions (Fig. 7C,D). These data
suggest that HS+MES had no adverse side effects on normal, lean
mice.
MES increased Akt phosphorylation through PI3K in
HepG2 cells
To further investigate the effect of MES on Akt phosphorylation,
we examined the phosphorylation status of Akt in vitro using HepG2
cells. This cell line was previously used to determine the role of
PI3K/Akt pathway in insulin signaling and, by incubating in high-
glucose medium, was used as in vitro model of insulin resistance
[34,35,36].Consistent withpreviousreport,HepG2 cells exposedto
high glucose concentration (25 mM) exhibited reduced insulin-
stimulated Akt phosphorylation (Fig. 8A, [34]). MES (5 V) with
pulse duration of 0.1 ms, which did not induce cell toxicity [25],
applied for 10 min to normal or high glucose-exposed cells
effectively increased the insulin-stimulated phosphorylation of Akt,
1 h after treatment of cells (Fig. 8B–8D). Next, we determined the
phosphorylation status of IRb subunit. MES enhanced the
phosphorylation of IRb consistent with the increase of Akt
phosphorylation (Fig. 8E). We also examined the effect of MES
on downstream molecules of insulin signaling. As expected, MES
promoted the tyrosine phosphorylation of YXXM motif in IRS
protein (IRS-1 and IRS-2) (Fig. 8F; pYXXM) that leads to the
activation of PI3K and Akt phosphorylation in the liver [37].
Furthermore, we observed that the Akt phosphorylation induced by
MES was suppressed in the presence of PI3K inhibitors, LY294002
and wortmannin (Fig. 8F; pAkt). Consistent with these results, PIP3
immunoreactivity was enhanced by MES treatment in insulin-
stimulated HepG2 cells compared with sham-treated control
(Fig. 8G). We detected that the enhancement of Akt phosphoryla-
tion peaked at 1 h after MES treatment and gradually decreased
thereafter (Fig. 8H). Taken together, MES affected the activation of
insulin signaling molecules, although the enhancement of insulin
signaling pathway by MES was sustained for only a short time.
Figure 5. HS+MES decreased the fat content in mice liver and adipose tissues. (A) Ventral aspect of representative high fat-fed mice sham-
treated (control) or treated with HS+MES with exposed peritoneal cavity, showing decrease of visible adipose tissues in treated mice. (B) Histological
staining with H&E of the visceral fat (mesenteric fat (MF), perinephric fat (PF) and epididymal fat (EF)) and subcutaneous fat (Sq) in high fat-fed control
and HS+MES-treated mice. Scale bars, 100 mm. (C and D) Mice were sacrificed after a 15-h fast at the 15
th week of treatment, and visceral fat (C) and
subcutaneous fat (D) weights were determined (n=8 per group). (E) Liver weight of control and HS+MES-treated mice was determined. Data are
presented as mean6S.E. (n=8 per group). *P,0.05 assessed by unpaired t test. (F) Staining of fat droplets by Oil Red O in liver tissues of control and
HS+MES-treated mice. Scale bars, (6100) 200 mm, (6600) 100 mm. (G) Total RNA, extracted from brown adipose tissues of high fat-fed control and
HS+MES-treated mice, was subjected to semi-quantitative RT-PCR. Relative amount of UCP1 mRNA was normalized to HPRT (internal control) and
quantified using Image Gauge software. Data are presented as mean6S.E. (n=3 per group). *P,0.05 assessed by unpaired t test.
doi:10.1371/journal.pone.0004068.g005
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PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e4068Figure 6. HS+MES ameliorated insulin resistance in db/db mice. (A–C) Blood glucose (A), serum insulin (B) and insulin tolerance (C) of sham-
treated or HS+MES-treated db/db mice (n=5 per group) were measured at the 12
th week of treatment in the 15-h (A and B) or 6-h (C) fasted state.
Symbols: black diamonds=control; white diamonds=HS+MES. (D and E) Mice were sacrificed after a 15-h fast at the 15
th week of HS+MES treatment.
Visceral fat (D) and subcutaneous fat (E) weights were determined. Data are presented as mean6S.E. (n=5 per group).
{P,0.1, *P,0.05, **P,0.01
assessed by unpaired t test.
doi:10.1371/journal.pone.0004068.g006
Figure 7. HS+MES had minimal effects on standard diet-fed mice. (A) Body weight of 6-week-old sham-treated (control) and HS+MES-treated
mice was measured once a week for 16 weeks during the course of treatment. (B–D) Daily food intake (B), blood glucose levels of fasted (C) and fed
mice (D) were measured every 2 weeks during the 16-week treatment. Data are presented as mean6S.E. (n=5 per group). Symbols: black
diamonds=control; white diamonds=HS+MES.
doi:10.1371/journal.pone.0004068.g007
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PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e4068Figure 8. MES increased Akt phosphorylation through PI3K pathway in HepG2 cells. (A) Cells were incubated in medium containing either
normal or high glucose concentration and were stimulated with insulin before harvesting. (B) Cells were incubated in medium containing either
normal or high glucose concentration and then treated with MES (5 V, 0.1 ms) for 10 min. After 1 h, cells were stimulated with insulin. (C and D)
Relative amount of p-Akt was normalized to total Akt in either normal (C) or high (D) glucose concentration, and quantified using Image Gauge
software. Data are presented as mean6S.E. (n=3 per group). ***P,0.001 assessed by unpaired t test. (E) Cells were treated with MES for 10 min. After
1 h, cells were stimulated with insulin. (F) Cells were treated with MES for 10 min with or without the PI3K inhibitors, LY294002 and Wortmannin.
After 1 h of re-incubation at 37uC, cells were stimulated with insulin. (G) HepG2 cells were treated with MES for 10 min. After 1 h, cells were
stimulated with insulin, stained with PIP3 and DAPI, and visualized by fluorescent microscope. Scale bars, 100 mm. (H) Cells were treated with MES for
10 min. After the indicated time of re-incubation at 37uC, cells were stimulated with insulin before protein extraction. For B–H, control cells in these
experiments were sham-treated.
doi:10.1371/journal.pone.0004068.g008
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through the increase of Hsp72 expression in HepG2 cells
Insulin-stimulated Akt phosphorylation has also been observed
to be up-regulated in Hsp72 transgenic mice [24]. The mechanism
of which is most probably through the inhibitory action of Hsp72
on JNK, which plays a role in insulin resistance [20,22]. To
investigate the effect of Hsp72 overexpression, we transfected
Hsp72 plasmid in HepG2 cells. The Akt phosphorylation induced
by insulin was enhanced upon Hsp72 overexpression (Fig. 9A,B).
We next applied HS together with MES to HepG2 cells and
determined the Hsp72 expression and the phosphorylation status
of Akt. The combination treatment of HS and MES for 10 min
increased the Hsp72 expression in protein lysates of HepG2 cells
(Fig. 9C) isolated 5 h after treatment. Consequently, this treatment
enhanced the insulin-stimulated Akt phosphorylation in HepG2
cells exposed to high glucose similar to Hsp72 overexpression
(Fig. 9D,E). Knockdown of Hsp72 by siRNA in these cells reduced
the effect of HS+MES (Fig. 9F), suggesting that the effect of
HS+MES is partly mediated by Hsp72.
To clarify the action of HS and MES on Akt activation, we
determined their time-dependent effect. Cells were treated for
10 min with HS and MES, and lysates were isolated at the
indicated time points. The combination of HS and MES induced a
sustained enhancement of Akt phosphorylation from 1 h up to 5 h
after treatment in insulin-stimulated, high glucose-exposed HepG2
cells (Fig. 9G). These results confirmed that MES activated Akt,
Figure 9. HS+MES promoted the phosphorylation of Akt in HepG2 cells. (A) Cells were transiently transfected with Hsp72-myc plasmid or
empty vector. After 24 h, cells were incubated in medium containing high concentration of D-glucose. Before harvesting, cells were stimulated with
insulin. (B) Relative amount of p-Akt was normalized to total Akt and quantified using Image Gauge software. Data are presented as mean6S.E. (n=3
per group). *P,0.05 assessed by unpaired t test. (C) Cells were treated with HS and/or MES for 10 min. After 5 h, cell lysates were extracted. (D) Cells
were treated with HS+MES for 10 min. After 5 h, cells were stimulated with insulin for 10 min before protein extraction. (E) Relative amount of p-Akt
was normalized to total Akt and quantified using Image Gauge software. Data are presented as mean6S.E. (n=3 per group). **P,0.01 assessed by
unpaired t test. (F) Cells were transiently transfected with Hsp72 siRNA or GL2 siRNA for 24 h, then incubated in medium containing high
concentration of D-glucose for 19 h. Cells were treated with HS+MES for 10 min. After 5 h, cells were stimulated with insulin. (G) Cells were treated
with HS+MES for 10 min. After the indicated time of re-incubation at 37uC, cells were stimulated with insulin before protein extraction. For (A, C, D, F,
G), lysates were subjected to immunoblotting with the indicated antibodies. For (C–G), control cells were sham-treated.
doi:10.1371/journal.pone.0004068.g009
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the level of phosphorylated Akt.
Discussion
Insulin resistance is a crucial risk factor for the development of
type 2 diabetes. Although the pathogenesis of insulin resistance is
largely unknown, studies have proven that it is due to a defect in
insulin signaling [11,14,16]. PI3K/Akt pathway is one of the
signaling cascades activated by insulin and plays a major role in
hepatic glucose homeostasis [35,38], and Akt knockout mice show
insulin resistance that later developed to a phenotype of type 2
diabetes [14]. These studies suggest that defective Akt signaling
contributes to the development of insulin resistance. It was
previously reported that electrical signals activate PI3K/Akt [8],
thus we investigated whether application of low-intensity current
could increase Akt phosphorylation and affect insulin signaling. In
addition, Hsp72 was also shown previously to alleviate insulin
resistance[24]. We showedhere that the use of low intensity current
together with short-duration HS activated Akt in vivo (Fig. 4A) and
resulted in higher insulin sensitivity, lower blood glucose level and
higher serum adiponectin in high fat-fed mice (Fig. 2–3). HS+MES
treatmentalsoledtoanimprovementofhepaticsteatosis(Fig.5E,F),
a condition which has been linked with insulin resistance [39,40].
The effect of HS+MES on insulin signaling is likely through the
capacity of electrical signal to trigger the activation of Akt (Fig. 8,
[8]) and of HS to up-regulate Hsp72, which in turn inhibits JNK
and activates the insulin signaling pathway (Fig. 4C, Fig. 9 [24,41]).
Although the core bodytemperature ofthemicewasless than 42uC,
the method of mild HS that we used was enough to induce the
expression of Hsp72 (Fig. 4D).
Type 2 diabetes and obesity have characteristics of inflamma-
tory conditions with increased blood levels of pro-inflammatory
cytokines, such as interleukin (IL)-6, IL-1 and TNF-a [42], which
attenuate insulin receptor signaling [43]. The anti-diabetic agent,
pioglitazone, has been reported to decrease TNF-a and increase
serum adiponectin in type 2 diabetic patients [44]. Thus, it is
notable that the combination treatment of HS and MES
significantly decreased serum TNF-a level and increased serum
adiponectin in mice chronically fed with high-fat diet (Fig. 3E,F).
One of the observations in this study is that although there was
no difference in body weight and food intake between control and
treated groups of high fat-fed mice (Fig. 2F,G) and db/db mice,
there was a significant decrease in the visceral fat and
subcutaneous fat weights in mice treated with the combination
of HS and MES (Fig. 5C–D, Fig. 6D–E). This might be due to an
increase in the muscle mass of the treated mice, as it has been
suggested that heat stress, which increases Hsp72 and calcineurin
levels, may cause muscle hypertrophy [45].
Our data indicated that one of the main target tissues of
HS+MES is the liver. Other target tissues, such as adipose tissues
and skeletal muscles, might also be affected by HS+MES, and are
involved in the observed amelioration of the diabetic phenotype.
In addition to the increased insulin signaling in the liver with
HS+MES treatment, we observed that HS+MES affected the
levels of serum TNF-a and adiponectin, which are adipocytokines
secreted by adipose tissues (Fig. 3E,F), as mentioned above.
HS+MES also enhanced the cell surface translocation in mice
skeletal muscle of GLUT4 (Fig. S1), the major regulatory molecule
for insulin-stimulated glucose uptake in skeletal muscles, indicating
an improved response to insulin stimulation in skeletal muscles.
These data suggest that HS+MES may directly affect major insulin
target tissues or may exert an anti-diabetic effect in one tissue,
leading to secondary effects in the other tissues.
Low-intensity current as well as heat shock have been applied as
treatment modalities in clinical setting for a range of diseases with
relatively few side effects [6,46]. The absence of observable
adverse effects of HS+MES treatment in normal mice (Fig. 7) in
our study suggests its safety, although it is necessary to assess the
long-term effects of this treatment. Due to technical limitations we
could not measure the extent of electrical conductance in cells and
tissues. Electrotherapeutic units of low voltage may produce
currents of intensities up to a few microamperes and milliamperes,
but measuring the current distribution of an applied electric
current in biological tissues is hampered by several factors.
Electrical charges in tissues are transferred by multiple mecha-
nisms such as the migration of ions, membrane capacitance, and
rotation of polar molecules [47,48,49]. Moreover, these electrical
properties vary between tissues. Different cell types show subtly
different responses to direct current electrical field due to variable
local tissue resistances, the extracellular matrix composition, the
coexistence of growth factors and neurotransmitters, and the level
of second messengers within the cells [50]. Because low-intensity
current and heat shock may have an impact on many cellular
processes and functions, we cannot rule out the possibility that
signaling pathways, other than the PI3K/Akt pathway, are
affected by HS+MES treatment to produce the observed effects.
Further investigation on the possible regulation of other signaling
molecules by HS+MES may be necessary to provide deeper
mechanistic insight to the effects of HS+MES. In conclusion, we
showed here that the combination of HS and MES treatment
ameliorated insulin resistance and decreased fat accumulation in
diabetes mouse models, in part, by enhancing Akt activation.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0004068.s001 (0.34 MB
PDF)
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